Collegium Pharmaceutical Inc. (NASDAQ:COLL)‘s stock had its “buy” rating reiterated by stock analysts at Jefferies Group in a research note issued on Thursday.

Several other research firms have also weighed in on COLL. Piper Jaffray Cos. set a $23.00 target price on Collegium Pharmaceutical and gave the company a “buy” rating in a research note on Thursday, August 11th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, September 14th. Zacks Investment Research raised Collegium Pharmaceutical from a “sell” rating to a “hold” rating in a research note on Wednesday, July 6th. Finally, Gabelli started coverage on Collegium Pharmaceutical in a research note on Tuesday, September 13th. They issued a “buy” rating and a $25.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and six have issued a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $27.60.

Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 12.82 on Thursday. The firm has a 50-day moving average price of $10.61 and a 200-day moving average price of $14.46. Collegium Pharmaceutical has a 1-year low of $8.24 and a 1-year high of $30.58. The company’s market capitalization is $301.63 million.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/22/collegium-pharmaceutical-inc-coll-rating-reiterated-by-jefferies-group.html

Collegium Pharmaceutical (NASDAQ:COLL) last released its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the consensus estimate of ($0.76) by $0.29. Equities analysts anticipate that Collegium Pharmaceutical will post ($3.86) earnings per share for the current year.

In other Collegium Pharmaceutical news, Director John A. Fallon purchased 2,375 shares of the stock in a transaction on Friday, August 12th. The stock was bought at an average cost of $10.59 per share, for a total transaction of $25,151.25. Following the completion of the acquisition, the director now directly owns 2,375 shares of the company’s stock, valued at $25,151.25. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 37.93% of the stock is owned by company insiders.

Large investors have recently made changes to their positions in the company. Goldman Sachs Group Inc. increased its stake in shares of Collegium Pharmaceutical by 47.7% in the first quarter. Goldman Sachs Group Inc. now owns 60,294 shares of the specialty pharmaceutical company’s stock valued at $1,094,000 after buying an additional 19,460 shares during the period. M&T Bank Corp acquired a new stake in shares of Collegium Pharmaceutical during the first quarter valued at about $287,000. Geode Capital Management LLC increased its stake in shares of Collegium Pharmaceutical by 74.9% in the first quarter. Geode Capital Management LLC now owns 78,903 shares of the specialty pharmaceutical company’s stock valued at $1,432,000 after buying an additional 33,783 shares during the period. Franklin Resources Inc. increased its stake in shares of Collegium Pharmaceutical by 155.8% in the first quarter. Franklin Resources Inc. now owns 829,599 shares of the specialty pharmaceutical company’s stock valued at $15,057,000 after buying an additional 505,299 shares during the period. Finally, Sabby Management LLC acquired a new stake in shares of Collegium Pharmaceutical during the first quarter valued at about $1,490,000. Institutional investors own 62.13% of the company’s stock.

About Collegium Pharmaceutical

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.

5 Day Chart for NASDAQ:COLL

Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.